Nelli Bejanyan Cell Therapy Facility Moffitt Cancer Center and Research Institute Biography Publications Institution JoVE Articles Nelli Bejanyan has not added a biography. If you are Nelli Bejanyan and would like to personalize this page please email our Author Liaison for assistance. Publications ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Transplantation and Cellular Therapy. 03, 2021 | Pubmed ID: 33781526 First-line Hypomethylating Agents for Patients with High Risk Chronic Myelomonocytic Leukaemia The Lancet. Haematology. 02, 2021 | Pubmed ID: 33513378 Prognostic Factors for Clinical Outcomes of Patients with Central Nervous System Leukemia Hematology/oncology and Stem Cell Therapy. Sep, 2021 | Pubmed ID: 33271117 Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study Transplantation and Cellular Therapy. 01, 2021 | Pubmed ID: 33010430 Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product Ana Marie Landin1, Cheryl Cox1, Bin Yu2, Nelli Bejanyan1,2, Marco Davila1,2, Linda Kelley1,2 1Cell Therapy Facility, Moffitt Cancer Center and Research Institute, 2Department of Immunology, Moffitt Cancer Center and Research Institute JoVE 62622 Cancer Research
Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product Ana Marie Landin1, Cheryl Cox1, Bin Yu2, Nelli Bejanyan1,2, Marco Davila1,2, Linda Kelley1,2 1Cell Therapy Facility, Moffitt Cancer Center and Research Institute, 2Department of Immunology, Moffitt Cancer Center and Research Institute JoVE 62622 Cancer Research
